Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034268 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00034268: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00034268 is a Phase 3 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034268, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs. 3. Whether LY900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed. LY900003 may not add any benefit to gemcitabine plus cisplatin.
Interventions
- DRUG LY900003
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Phase | Phase 3 |
What the finished NCT00034268 record still lists
NCT00034268 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which LY900003 is the first listed.
NCT00034268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034268 about?
NCT00034268 is a clinical study titled "A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer". The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combinat...
What is the current status of trial NCT00034268?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-03.
What interventions are being tested in trial NCT00034268?
The interventions under investigation include: LY900003 (DRUG).
Who is sponsoring clinical trial NCT00034268?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia